Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9397293 | 0.90 | SLC22A12 (0.45) | ALKSLC22A12CYP1A2CYP2C19HTT | |
| SCHEMBL360254 | 0.84 | SLC22A12 (0.51) | ALKSLC22A12CYP1A2CYP2C19HTT | |
| SCHEMBL28164080 | 0.79 | TLR8 (0.54) | HTTALOX15EGFRTLR8KDM4E | |
| SCHEMBL29509132 | 0.79 | TLR8 (0.54) | HTTALOX15EGFRTLR8KDM4E | |
| SCHEMBL4470963 | 0.79 | ALK (0.53) | ALKSLC22A12CYP1A2CYP2C19HTT | |
| SCHEMBL29896720 | 0.79 | ALK (0.53) | ALKSLC22A12CYP1A2CYP2C19HTT | |
| SCHEMBL23498024 | 0.78 | SLC22A12 (0.37) | ALKSLC22A12CYP2C19GAKEGFR | |
| SCHEMBL2086578 | 0.78 | EGFR (0.53) | ALKHTTGAKEGFRTLR8 | |
| Bromide SCHEMBL11522045 | 0.78 | ALK (0.51) | ALKSLC22A12CYP1A2CYP2C19HTT | |
| SCHEMBL1496398 | 0.77 | ALK (0.51) | ALKSLC22A12CYP1A2CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-4447435-A | HYPOTENSIVE AGENTS | THE BOOTS COMPANY PLC (GB) | 1984-05-08 | — | — | US | disclosed |
| US-4442109-A | 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension | THE BOOTS COMPANY LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | ALK 2180/4885SLC22A12 3891/4885CYP1A2 2702/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | ALK 4829/4885SLC22A12 996/4885CYP1A2 556/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | ALK 1024/4885SLC22A12 4799/4885CYP1A2 2461/4885 |
| US-12391675-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | ALK 4810/4885SLC22A12 1098/4885CYP1A2 667/4885 |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, PTK2B | ALK 300/4885SLC22A12 3969/4885CYP1A2 4184/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | ALK 3385/4885SLC22A12 3641/4885CYP1A2 637/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ALK 1901/4885SLC22A12 2238/4885CYP1A2 1963/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | ALK 3020/4885SLC22A12 4432/4885CYP1A2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.